Loxoprofen
As of the edition of 20 October 2026, Loxoprofen is a small molecule: marketed, first approved in 2006 (JP); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2006
- Kind
- Small molecule
- First approved
- 23 January 2006 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Lead Chemical
- Registered trials
- 8, 0 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Cancer; Hormones; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Loxoprofen.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 0 |
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lead Chemical | Originator | 2006 to now |